BioCardia, Inc. (BCDA) shares soared 48.13 percent, gaining $0.4423 to $1.3613 on Friday after the company announced that it received meeting minutes from the U.S. Food and Drug Administration confirming that its ongoing CardiAMP Heart Failure II Trial may support a Premarket Approval application for the CardiAMP Cell Therapy System in patients with ischemic heart failure with reduced ejection fraction (HFrEF).
The stock is currently trading at $1.3613, compared with its previous close of $0.9190 on the Nasdaq. During the session, it opened at $1.1950 and traded between $1.0800 and $1.8000. Trading volume surged to 126.24 million shares, dramatically exceeding its average volume of 164,233 shares.
The FDA feedback represents a significant regulatory milestone, as PMA is the agency's most rigorous approval pathway for high-risk medical devices. The company noted that the completed CardiAMP HF clinical data could serve as the first of two trials supporting a future PMA submission.
BioCardia shares have traded between $0.8400 and $2.4500 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.